Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
InnovAge Diversifies Board of Directors with New Independent Director InnovAge announced the appointment of Patty Fontneau to its Board of...
Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancerFLORHAM...
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second...
MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an...
- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which...
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize...
Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on...
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies...
LAS VEGAS, NV, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the signing...
Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the...
Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway...
Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory propertiesSAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma,...
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023...
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, March 30, 2023 (GLOBE NEWSWIRE) -- Atlas Global Brands Inc. (“Atlas Global” or...
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.),...